Moreover, denosumab is currently used to treat bone fractures of metastatic disease and RANKL inhibition has been extensively studied in preclinical tumour models [47] and is now proven as a preventive strategy for women carrying BRCA1 mutations and high risk of BC [20]. Here, BRCA1 is linked to metastatic neoplasm.